EHP-102
![]() | |
| Clinical data | |
|---|---|
| Other names | EHP102; VCE-003.2; VCE003.2 |
| Routes of administration | Oral[1] |
| Drug class | Cannabinoid CB2 receptor agonist; PPARγ agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H35NO3 |
| Molar mass | 373.537 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease.[1][2][3][4] It is taken orally.[1] The drug is a derivative of cannabigerol (CBG).[4] It is under development by Emerald Health Sciences.[1][2][3] As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.[1][2][3]
See also
References
- 1 2 3 4 5 "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.
- 1 2 3 "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.
- 1 2 3 Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
- 1 2 Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| PPARαTooltip Peroxisome proliferator-activated receptor alpha |
|
|---|---|
| PPARδTooltip Peroxisome proliferator-activated receptor delta |
|
| PPARγTooltip Peroxisome proliferator-activated receptor gamma |
|
| Non-selective | |
| |
Categories:
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.
